Innate Pharma (NASDAQ:IPHA) Shares Down 0.7% – Here’s What Happened

Shares of Innate Pharma S.A. Sponsored ADR (NASDAQ:IPHA) were down 0.7% on Monday . The company traded as low as $1.43 and last traded at $1.43. Approximately 36,983 shares traded hands during mid-day trading, an increase of 21% from the average daily volume of 30,450 shares. The stock had previously closed at $1.44.

Analysts Set New Price Targets

A number of research analysts recently weighed in on IPHA shares. BTIG Research started coverage on shares of Innate Pharma in a report on Thursday, March 12th. They issued a “buy” rating and a $8.00 target price for the company. HC Wainwright reissued a “buy” rating and issued a $5.00 target price on shares of Innate Pharma in a report on Tuesday, April 7th. Finally, Weiss Ratings reissued a “sell (e+)” rating on shares of Innate Pharma in a report on Tuesday, April 21st. One analyst has rated the stock with a Strong Buy rating, one has given a Buy rating, one has issued a Hold rating and one has given a Sell rating to the company. According to MarketBeat.com, the stock currently has a consensus rating of “Moderate Buy” and an average price target of $5.00.

Innate Pharma Price Performance

The business’s fifty day moving average is $1.47 and its two-hundred day moving average is $1.72.

Innate Pharma (NASDAQ:IPHA) last issued its quarterly earnings results on Saturday, February 14th. The company reported ($0.18) earnings per share (EPS) for the quarter. The company had revenue of $2.41 million during the quarter. As a group, research analysts predict that Innate Pharma S.A. Sponsored ADR will post -0.55 EPS for the current year.

Institutional Trading of Innate Pharma

A number of institutional investors have recently bought and sold shares of IPHA. Jane Street Group LLC bought a new stake in Innate Pharma in the fourth quarter worth $162,000. Millennium Management LLC bought a new stake in Innate Pharma in the fourth quarter worth $36,000. Finally, OLD Mission Capital LLC bought a new stake in Innate Pharma in the fourth quarter worth $50,000. 0.16% of the stock is currently owned by institutional investors.

About Innate Pharma

Innate Pharma SA is a clinical-stage biotechnology company specializing in the discovery and development of antibody-based therapies that harness the body’s innate immune system to combat cancer. Founded in 1999 and headquartered in Marseille, France, the company pioneers novel monoclonal antibodies designed to activate natural killer cells and macrophages, offering a complementary approach to existing immuno-oncology treatments.

The company’s lead program, monalizumab, targets the NKG2A immune checkpoint receptor and is being developed in collaboration with AstraZeneca.